title: Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia.
abstract: Sorafenib is a multi-kinase inhibitor with activity against several intracellular kinases which may play a role in the pathogenesis of acute myeloid leukemia (AML). In vitro data and results from early clinical trials suggest that sorafenib might be an effective drug for the treatment of AML. However, clinical data are still sparse, and there are only a few reported cases of monotherapy. The aim of the present research was to collect clinical data on efficacy and safety in a systematic way by conducting a survey on clinical experience with sorafenib. Thirty institutions were asked to document all patients treated with sorafenib diagnosed with AML. Of all 29 evaluable patients, six (21%) responded to sorafenib containing treatment by achieving a complete remission (CR, n = 2) or complete remission with incomplete platelet recovery (CRi, n = 4). In 23 patients receiving sorafenib as monotherapy, the CRi rate amounted to 13% and no CRs were documented. Of the 18 FLT-ITD positive patients with sorafenib monotherapy, two patients achieved a CRi (11%). In five FLT3-ITD negative cases, one CRi was documented (20%). Our results suggest the potential ability of the drug to induce remissions in refractory or relapsed AML even when given as monotherapy.
authors: Medizinische Klinik und Poliklinik I, Universitätsklinikum, Dresden, Germany. christoph.roellig@uniklinikum-dresden.de
authors: Christoph
authors: C
authors: Röllig
authors: Christian
authors: C
authors: Brandts
authors: Shabnam
authors: S
authors: Shaid
authors: Marcus
authors: M
authors: Hentrich
authors: Alwin
authors: A
authors: Krämer
authors: Christian
authors: C
authors: Junghanß
authors: Eberhard
authors: E
authors: Schleyer
authors: Carsten
authors: C
authors: Müller-Tidow
authors: Wolfgang E
authors: WE
authors: Berdel
authors: Barbara
authors: B
authors: Ritter
authors: Karl-Heinz
authors: KH
authors: Pflüger
authors: Michael
authors: M
authors: Kramer
authors: Martina
authors: M
authors: Haibach
authors: Gerhard
authors: G
authors: Ehninger
authors: Hubert
authors: H
authors: Serve
authors: Stefan W
authors: SW
authors: Krause
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000009:adverse effects / Q000627:therapeutic use*; D003625:Data Collection; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D012074:Remission Induction; D012189:Retrospective Studies; D000077157:Sorafenib; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib